phase i dose expansion results of cyt-0851 plus capecitabine in platinum-resistant ovarian cancer
Published 3 months ago • 41 plays • Length 0:35Download video MP4
Download video MP3
Similar videos
-
1:19
relacorilant nab-paclitaxel in recurrent, platinum-resistant ovarian cancer
-
6:35
first-in-human results of cdk2/4/6 inhibition in breast and ovarian cancer
-
4:46
#esmo19: forward i (gog 3011) study for platinum-resistant ovarian cancer
-
6:54
adc in platinum-resistant ovarian cancer
-
1:41
unmet clinical needs for platinum-resistant ovarian cancer patients
-
59:55
tackling platinum resistant ovarian cancer
-
2:19
dr. moore on anticipated impact of the mirasol trial in platinum-resistant ovarian cancer
-
24:53
parp inhibitors in platinum sensitive & platinum resistant ovarian cancers
-
6:57
bevacizumab in platinum-resistant ovarian cancer
-
5:03
forward i: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer
-
2:20
dr. matulonis discusses niraparib/pembrolizumab combo in platinum-resistant ovarian cancer
-
33:15
ovarian cancer: standards of care and new opportunities - dr. robert coleman
-
2:03
reproduction: does single-strand dna break repair capacity influence oocyte maintenance and quality?
-
14:46
managing platinum-resistant ovarian cancer
-
23:15
is it time to change upfront chemotherapy for ovarian cancer?
-
1:41
dr. konner on preferred platinum doublets in recurrent ovarian cancer
-
9:21
phase ib dose escalation trial of sar650984 improves outcomes in relapsed or refractory myeloma
-
0:41
liquid biopsy: monitoring recurrence in high-risk ovarian cancer
-
7:06
contextualized new data on platinum resistant ovarian cancer